C4 THERAPEUTICS INC (CCCC) Stock Fundamental Analysis
USA - NASDAQ:CCCC - US12529R1077 - Common Stock
2.311 USD
-0.03 (-1.24%)
Taking everything into account, CCCC scores 3 out of 10 in our fundamental rating. CCCC was compared to 531 industry peers in the Biotechnology industry. The financial health of CCCC is average, but there are quite some concerns on its profitability. CCCC is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
CCCC had negative earnings in the past year.
In the past year CCCC has reported a negative cash flow from operations.
In the past 5 years CCCC always reported negative net income.
In the past 5 years CCCC always reported negative operating cash flow.
1.2 Ratios
CCCC's Return On Assets of -37.63% is fine compared to the rest of the industry. CCCC outperforms 61.02% of its industry peers.
CCCC's Return On Equity of -64.10% is fine compared to the rest of the industry. CCCC outperforms 60.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -37.63% | ||
| ROE | -64.1% | ||
| ROIC | N/A |
ROA(3y)-31.69%
ROA(5y)-25.64%
ROE(3y)-48.97%
ROE(5y)-38.41%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CCCC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CCCC does not have a ROIC to compare to the WACC, probably because it is not profitable.
CCCC has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CCCC has been increased compared to 5 years ago.
CCCC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
CCCC has an Altman-Z score of -2.70. This is a bad value and indicates that CCCC is not financially healthy and even has some risk of bankruptcy.
CCCC has a Altman-Z score of -2.70. This is comparable to the rest of the industry: CCCC outperforms 48.02% of its industry peers.
There is no outstanding debt for CCCC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.7 |
ROIC/WACCN/A
WACC8.75%
2.3 Liquidity
CCCC has a Current Ratio of 5.06. This indicates that CCCC is financially healthy and has no problem in meeting its short term obligations.
CCCC's Current ratio of 5.06 is in line compared to the rest of the industry. CCCC outperforms 56.69% of its industry peers.
CCCC has a Quick Ratio of 5.06. This indicates that CCCC is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of CCCC (5.06) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.06 | ||
| Quick Ratio | 5.06 |
3. Growth
3.1 Past
CCCC shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.91%.
CCCC shows a strong growth in Revenue. In the last year, the Revenue has grown by 71.44%.
CCCC shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.73% yearly.
EPS 1Y (TTM)2.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25.71%
Revenue 1Y (TTM)71.44%
Revenue growth 3Y-8.06%
Revenue growth 5Y10.73%
Sales Q2Q%-26.9%
3.2 Future
CCCC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.08% yearly.
CCCC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 103.57% yearly.
EPS Next Y-4.99%
EPS Next 2Y-5.12%
EPS Next 3Y0.57%
EPS Next 5Y29.08%
Revenue Next Year-21.4%
Revenue Next 2Y-19.86%
Revenue Next 3Y-13.72%
Revenue Next 5Y103.57%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CCCC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CCCC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.12%
EPS Next 3Y0.57%
5. Dividend
5.1 Amount
No dividends for CCCC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:CCCC (11/10/2025, 12:45:05 PM)
2.311
-0.03 (-1.24%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners67.33%
Inst Owner Change0.3%
Ins Owners2.27%
Ins Owner Change2.22%
Market Cap214.69M
Revenue(TTM)35.58M
Net Income(TTM)-111.58M
Analysts86.15
Price Target12.24 (429.64%)
Short Float %5.06%
Short Ratio1.93
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.46%
Min EPS beat(2)5.54%
Max EPS beat(2)19.39%
EPS beat(4)3
Avg EPS beat(4)8.52%
Min EPS beat(4)-0.55%
Max EPS beat(4)19.39%
EPS beat(8)5
Avg EPS beat(8)9.17%
EPS beat(12)7
Avg EPS beat(12)6.61%
EPS beat(16)10
Avg EPS beat(16)9.58%
Revenue beat(2)1
Avg Revenue beat(2)28.1%
Min Revenue beat(2)-3.26%
Max Revenue beat(2)59.46%
Revenue beat(4)2
Avg Revenue beat(4)70.66%
Min Revenue beat(4)-3.26%
Max Revenue beat(4)227.41%
Revenue beat(8)5
Avg Revenue beat(8)58.07%
Revenue beat(12)5
Avg Revenue beat(12)23.44%
Revenue beat(16)8
Avg Revenue beat(16)33.71%
PT rev (1m)-20%
PT rev (3m)-24.05%
EPS NQ rev (1m)0%
EPS NQ rev (3m)9.34%
EPS NY rev (1m)3.06%
EPS NY rev (3m)10.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-7.64%
Revenue NY rev (1m)4.1%
Revenue NY rev (3m)10.58%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 6.27 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.23 | ||
| P/tB | 1.23 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.67
EYN/A
EPS(NY)-1.67
Fwd EYN/A
FCF(TTM)-0.94
FCFYN/A
OCF(TTM)-0.94
OCFYN/A
SpS0.37
BVpS1.87
TBVpS1.87
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -37.63% | ||
| ROE | -64.1% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-31.69%
ROA(5y)-25.64%
ROE(3y)-48.97%
ROE(5y)-38.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 8.43% | ||
| Cap/Sales | 0.49% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.06 | ||
| Quick Ratio | 5.06 | ||
| Altman-Z | -2.7 |
F-Score4
WACC8.75%
ROIC/WACCN/A
Cap/Depr(3y)142.71%
Cap/Depr(5y)110.83%
Cap/Sales(3y)8.81%
Cap/Sales(5y)6.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25.71%
EPS Next Y-4.99%
EPS Next 2Y-5.12%
EPS Next 3Y0.57%
EPS Next 5Y29.08%
Revenue 1Y (TTM)71.44%
Revenue growth 3Y-8.06%
Revenue growth 5Y10.73%
Sales Q2Q%-26.9%
Revenue Next Year-21.4%
Revenue Next 2Y-19.86%
Revenue Next 3Y-13.72%
Revenue Next 5Y103.57%
EBIT growth 1Y-6.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2.41%
EBIT Next 3Y-7.58%
EBIT Next 5YN/A
FCF growth 1Y23.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y20.01%
OCF growth 3YN/A
OCF growth 5YN/A
C4 THERAPEUTICS INC / CCCC FAQ
What is the ChartMill fundamental rating of C4 THERAPEUTICS INC (CCCC) stock?
ChartMill assigns a fundamental rating of 3 / 10 to CCCC.
What is the valuation status for CCCC stock?
ChartMill assigns a valuation rating of 0 / 10 to C4 THERAPEUTICS INC (CCCC). This can be considered as Overvalued.
Can you provide the profitability details for C4 THERAPEUTICS INC?
C4 THERAPEUTICS INC (CCCC) has a profitability rating of 1 / 10.
Can you provide the financial health for CCCC stock?
The financial health rating of C4 THERAPEUTICS INC (CCCC) is 6 / 10.